Denali Therapeutics

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$0
$0
$0
$0
Gross Profit
-1,942
-2,162
EBITDA
-127,227
-120,918
-114,651
-130,090
EBIT
-129,846
-123,187
-116,593
-132,252
Net Income
-114,753
-107,192
-99,026
-101,802
Net Change In Cash
0
0
0
0
Free Cash Flow
-88,807
-63,023
-96,006
-115,770
Cash
174,960
90,636
74,679
60,574
Basic Shares
170,086
169,456
168,831
149,404

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$0
$330,531
$108,463
$48,661
Gross Profit
313,805
101,431
48,661
EBITDA
-487,341
-179,973
-330,361
-287,158
EBIT
-196,699
-337,393
-295,751
Net Income
-422,773
-145,224
-325,991
-290,581
Net Change In Cash
0
330,531
108,463
48,661
Cost of Revenue
-213,667
Free Cash Flow
-363,606
-370,930
-262,549
-219,889
Cash
174,960
127,106
218,044
293,477
Basic Shares
164,473
137,370
125,530
121,524

Earnings Calls

Quarter EPS
2024-12-31
-$0.67
2024-09-30
-$0.63
2024-06-30
-$0.59
2024-03-31
-$0.78